ABT Innovations Inc. develops and commercializes the use of multiple peptide products (small proteins) for applications in a number of areas, including inflammatory medications to vaccine adjuvants. ABT Innovations operates together with the University of British Columbia, through a worldwide, exclusive license agreement, that allows ABT (subject to certain restrictions) the ability to use and sublicense core technology developed through research carried out in Dr. Robert E.W. Hancock’s lab at the University of British Columbia. The fundamental interest of Dr. Hancock and his laboratory is in designing new therapeutic strategies to treat infections and inflammation in light of the increasing antibiotic resistance coupled with a dearth of new antibiotic discovery.

ABT Innovation’s business strategy consists of providing novel treatment options for antimicrobial resistant infections. Specifically, the company is targeting hard-to-treat biofilm-associated infections that represent nearly two-thirds of all infections but are notably resistant to conventional antibiotics. In addition, ABT Innovation’s peptide technology addresses the underlying inflammation associated with infections and promotes healthy immune responses in patients.  The company  is primarily interested in developing novel treatments to address common inflammatory biofilm-associated diseases such as Chronic Rhinosinusitis (CRS) and biofilm-infected chronic wounds.

ABT Innovations has also been developing supplemental indications related to the diverse activity profiles of their synthetic peptide technology, mainly through partnerships with various academic and commercial entities. As such, in vitro and/or in vivo studies have been carried out in the fields of dental infections, abscesses, wounds and burns, and various inflammatory diseases. Other studies have tested ABT Innovations technology in veterinary applications as well as their use as vaccine adjuvants.  ABT Innovations is always open to new partnerships and collaborations to further expand the utility of their peptide technology in infectious disease management and treatment of inflammatory disorders.

ABT Innovations Inc. is a private company established in 2015.